Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response

Michael E. O'Dwyer; Ronan Swords; Arnon Nagler; Mary Frances McMullin; Philipp D. le Coutre; Stephen E. Langabeer; Alberto Alvarez-Iglesias; Hongxin Fan; Richard C. Woodman; Francis J. Giles; Eibhlin Conneally

doi:10.1016/j.leukres.2013.11.016

Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response

Michael E. O'Dwyer, Ronan Swords, Arnon Nagler, Mary Frances McMullin, Philipp D. le Coutre, Stephen E. Langabeer, Alberto Alvarez-Iglesias, Hongxin Fan, Richard C. Woodman, Francis J. Giles, Eibhlin Conneally

Pathology

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p= 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.

Original language	English (US)
Pages (from-to)	310-315
Number of pages	6
Journal	Leukemia Research
Volume	38
Issue number	3
DOIs	https://doi.org/10.1016/j.leukres.2013.11.016
State	Published - Mar 2014

Keywords

CML BCR-ABL
Minimal residual disease
Molecular diagnostics
Nilotinib

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2013.11.016

Cite this

O'Dwyer, M. E., Swords, R., Nagler, A., McMullin, M. F., le Coutre, P. D., Langabeer, S. E., Alvarez-Iglesias, A., Fan, H., Woodman, R. C., Giles, F. J., & Conneally, E. (2014). Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response. Leukemia Research, 38(3), 310-315. https://doi.org/10.1016/j.leukres.2013.11.016

O'Dwyer, ME, Swords, R, Nagler, A, McMullin, MF, le Coutre, PD, Langabeer, SE, Alvarez-Iglesias, A, Fan, H, Woodman, RC, Giles, FJ & Conneally, E 2014, 'Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response', Leukemia Research, vol. 38, no. 3, pp. 310-315. https://doi.org/10.1016/j.leukres.2013.11.016

@article{43c99f1ecb344b148d571e7c8b02c64d,

title = "Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response",

abstract = "Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor{\texttrademark} PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p= 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor{\texttrademark} system merits further investigation in this setting.",

keywords = "CML BCR-ABL, Minimal residual disease, Molecular diagnostics, Nilotinib",

author = "O'Dwyer, {Michael E.} and Ronan Swords and Arnon Nagler and McMullin, {Mary Frances} and {le Coutre}, {Philipp D.} and Langabeer, {Stephen E.} and Alberto Alvarez-Iglesias and Hongxin Fan and Woodman, {Richard C.} and Giles, {Francis J.} and Eibhlin Conneally",

note = "Funding Information: MEOD, RS, AN, FJG, PDLC, MFMM and EC have consulted for, and received research funding from, Novartis. RCW is a Novartis employee and stockholder. ",

year = "2014",

month = mar,

doi = "10.1016/j.leukres.2013.11.016",

language = "English (US)",

volume = "38",

pages = "310--315",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "3",

}

TY - JOUR

T1 - Nilotinib 300mg BID as frontline treatment of CML

T2 - Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response

AU - O'Dwyer, Michael E.

AU - Swords, Ronan

AU - Nagler, Arnon

AU - McMullin, Mary Frances

AU - le Coutre, Philipp D.

AU - Langabeer, Stephen E.

AU - Alvarez-Iglesias, Alberto

AU - Fan, Hongxin

AU - Woodman, Richard C.

AU - Giles, Francis J.

AU - Conneally, Eibhlin

N1 - Funding Information: MEOD, RS, AN, FJG, PDLC, MFMM and EC have consulted for, and received research funding from, Novartis. RCW is a Novartis employee and stockholder.

PY - 2014/3

Y1 - 2014/3

N2 - Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p= 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.

AB - Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p= 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.

KW - CML BCR-ABL

KW - Minimal residual disease

KW - Molecular diagnostics

KW - Nilotinib

UR - http://www.scopus.com/inward/record.url?scp=84894263290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894263290&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.11.016

DO - 10.1016/j.leukres.2013.11.016

M3 - Article

C2 - 24333114

AN - SCOPUS:84894263290

VL - 38

SP - 310

EP - 315

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 3

ER -

Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this